This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CDNF / Cerebral dopamine neurotrophic factor · IHC design guide
Design Immunohistochemistry for CDNF
Plan chromogenic CDNF IHC on paraffin sections using cytoplasmic and nuclear staining as a tentative tissue reference (HPA tissue IHC). Liver hepatocytes show high staining, but the HPA tissue profile has uncertain reliability (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CDNF Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Cytoplasmic and nuclear tissue staining (HPA tissue IHC) | |
| Staining pattern | Most tissues show cytoplasmic and nuclear staining (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Adrenal gland+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Secreted CDNF may weaken RNA–staining agreement (HPA tissue IHC) | |
| Regulation | No specific expression regulator reported (UniProt) | |
| Isoform / epitope | 2 isoforms; signal peptide 1–24 is cleaved; epitope map unknown (UniProt) |
Section 1
Recommended CDNF IHC & IF Protocols
The catalog antibody’s IHC-P protocol is accompanied by published CDNF chromogenic IHC methods for paraffin, free-floating, and cryostat brain sections (PMC9941578; PMC6580362; PMC7645584; PMC10593617).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet A10069-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-CDNF, 2.5 μg/mL (datasheet A10069-1) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CDNF-positive staining in glandular cells of adrenal gland (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression in most tissues. No signal in the no-primary control. |
💡Decision noteFor paraffin sections, start with citrate pH 6.0 HIER at 95–98 °C for 20 min (page retrieval); published protocols used other retrieval conditions (PMC9941578; PMC6580362).
Section 2
What Is the Expected CDNF Staining Pattern?
CDNF is a secreted protein with no transmembrane segment (UniProt Q49AH0 topology). HPA reports cytoplasmic and nuclear IHC staining in most tissues, including high staining in hepatocytes, pancreatic exocrine glandular cells, and skeletal myocytes (HPA tissue IHC). Treat these as provisional reference patterns: tissue IHC reliability is Uncertain because antibody staining and RNA expression show low consistency (HPA tissue IHC reliability).
| Cytoplasmic staining, with or without nuclear staining, in hepatocytes or pancreatic exocrine glandular cells. | This matches compartments reported across tissues and cells scored High by HPA (HPA tissue IHC). Score each compartment separately; neither nuclear staining nor intensity alone confirms specificity, because the tissue pattern has Uncertain reliability (HPA tissue IHC reliability). |
| A sharp plasma membrane outline dominates the signal. | A membrane restricted pattern is difficult to reconcile with CDNF's secreted annotation and lack of a transmembrane segment (UniProt Q49AH0 topology). Check the control slide and antibody specificity before assigning it to CDNF; extracellular signal alone is not evidence of a membrane anchored protein. |
| Strong staining occurs mainly in adipocytes or oral mucosal squamous epithelial cells. | HPA reports CDNF as Not detected in those respective cells (HPA tissue IHC). Review cell identification and controls for cross reactivity or endogenous detection activity (general IHC practice). The HPA comparison is a warning flag, not proof that every positive cell is artefactual (HPA tissue IHC reliability). |
| Color spreads across cells and surrounding tissue without clear cell boundaries. | Diffuse background cannot establish which cells contain CDNF (general IHC practice). Because CDNF is secreted, some protein may occur away from its producing cells (UniProt Q49AH0 subcellular annotation; HPA tissue IHC reliability). Judge specificity against a negative reagent control and the expected cellular pattern. |
| No signal appears in a section of liver or pancreas that contains the relevant cells. | HPA scores hepatocytes and pancreatic exocrine glandular cells High, making them practical reference tissues (HPA tissue IHC). Confirm tissue integrity and the detection controls, then assess the IHC workflow (general IHC practice). A blank section does not by itself establish absent CDNF expression. |
💡Expected CDNF appearanceA plausible positive shows discernible cytoplasmic, sometimes nuclear, staining in HPA High cells such as hepatocytes; intensity may be strong, while a dominant membrane rim or uniform haze warrants review (HPA tissue IHC; UniProt Q49AH0 topology; general IHC practice).
| Secretion and processing (UniProt Q49AH0). | CDNF has a signal peptide at residues 1–24 and a mature chain at 25–187 (UniProt Q49AH0 processing). A secreted protein may be seen apart from cells that make it; interpret spatial separation cautiously (UniProt Q49AH0 subcellular annotation; HPA tissue IHC reliability). |
| Reported tissue pattern and reliability (HPA tissue IHC). | HPA scores skeletal myocytes, respiratory epithelial cells in bronchus, and thyroid glandular cells High, alongside liver and pancreas (HPA tissue IHC). Its overall IHC reliability is Uncertain, so these are comparison patterns rather than independently verified CDNF positive controls (HPA tissue IHC reliability). |
| Antibody validation (HPA antibodies). | The listed antibody, HPA044587, has an Uncertain IHC status (HPA antibodies). Reproduction with this same antibody alone cannot resolve specificity; compare its cell distribution with HPA observations and appropriate reagent controls (HPA tissue IHC; general IHC practice). |
| RNA versus protein location (HPA tissue IHC). | HPA reports tissue enhanced RNA in skeletal muscle and tongue, while its protein pattern spans many tissues (HPA tissue IHC). HPA notes that secretion can separate RNA and protein locations and complicate correlation; do not infer a tissue's IHC intensity directly from its RNA category (HPA tissue IHC reliability). |
| Can IF/ICC confirm the compartment? | HPA lists CDNF as Secreted but provides no main subcellular location or cell line ICC-IF images (HPA subcellular). IF/ICC therefore has no HPA image pattern here that independently settles the nuclear versus cytoplasmic IHC interpretation; assess that application in its own guide. |
| Situation | Likely cause | Next action |
|---|---|---|
| The positive reference tissue is blank. | The detection run or tissue section may have failed (general IHC practice); HPA's High score is an uncertain reference (HPA tissue IHC). | Check tissue morphology and reagent controls, then review retrieval, antibody dilution, and detection against the IHC-validated antibody's instructions (general IHC practice). Avoid calling a biologically negative sample from one blank run. |
| All tissues show similar brown haze. | Nonspecific reagent binding, excess primary antibody, or endogenous detection activity may obscure cellular signal (general IHC practice). | Compare a no-primary control and a low-staining reference cell population; review blocking, antibody dilution, washing, and detection settings (general IHC practice; HPA tissue IHC: adipocytes Not detected). |
| Only nuclei stain strongly. | HPA reports nuclear as well as cytoplasmic expression, but its tissue IHC reliability is Uncertain (HPA tissue IHC). | Record nuclear and cytoplasmic scores separately. Compare with HPA High cell populations and reagent controls before interpreting nucleus-only staining as CDNF (HPA tissue IHC; general IHC practice). |
| A membrane rim is scored as positive CDNF. | CDNF has no transmembrane segment (UniProt Q49AH0 topology). | Recheck cell boundaries and negative reagent controls, and document the rim as a discordant pattern (general IHC practice). Do not merge it with cytoplasmic staining when scoring. |
| Adipocytes stain as strongly as hepatocytes. | That reverses the HPA cell comparison: adipocytes are Not detected and hepatocytes are High (HPA tissue IHC). | Verify both cell types on the section; assess cross reactivity and endogenous detection activity with controls before attributing the adipocyte signal to CDNF (general IHC practice). |
| A candidate tissue disagrees with its RNA profile. | Secreted CDNF may have different RNA and protein locations, and HPA reports low staining–RNA consistency (UniProt Q49AH0 subcellular annotation; HPA tissue IHC reliability). | Report the observed cell and compartment pattern as IHC data, with the HPA reliability caveat. Compare matched tissue sections and controls; do not force staining intensity to follow RNA abundance (general IHC practice). |
Experiment evidence
IHC & IF images showing CDNF staining
A10069-1 · IHCImmunohistochemistry of CDNF in human brain tissue with CDNF antibody at 2.5 μg/mL.
A10069-1 · IHCImmunohistochemistry of CDNF in mouse brain tissue with CDNF Antibody at 5 μg/mL.
A10069-1 · IFImmunofluorescence of CDNF in Human Brain cells with CDNF antibody at 20 μg/mL.
A10069 · IHCImmunohistochemical analysis of paraffin-embedded human-liver, antibody was diluted at 1:200
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000185267-CDNF/tissue/cerebral+cortex#imid_11922231
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000185267-CDNF/tissue/colon#imid_11922165
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000185267-CDNF/tissue/liver#imid_11922158
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000185267-CDNF/tissue/kidney#imid_11922159
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CDNF IHC & IF
🧪Run liver first: hepatocytes should stain (HPA: High in liver hepatocytes). Use oral mucosa as the negative tissue (HPA: Not detected in squamous epithelial cells); on the liver slide, cells outside the hepatocyte compartment that remain unstained should show only baseline background, but HPA does not validate those cells as CDNF-negative.
Positive control tissue: Adrenal gland (Glandular cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for CDNF; derive a cell-line control from the positive tissue's cell type (Glandular cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only control, a concentration-matched isotype control appropriate to the primary antibody’s host species and clonality, and, if available, a CDNF-knockout specimen as a biological negative (standard IHC practice). For chromogenic liver IHC, quench endogenous peroxidase and block or avoid endogenous biotin when using avidin–biotin detection (standard IHC practice).
⚠️Feasibility: The A10069-1 brain IHC caption reports 2.5 µg/mL but leaves the fixative unreported; the supplied evidence gives no CDNF-specific fixation window or antigen-retrieval dependence (A10069-1 tissue-IHC caption). These data do not establish whether frozen sections or IF would be easier; assess extracellular as well as cellular staining because CDNF is secreted (UniProt Q49AH0: Secreted). In liver, endogenous biotin can complicate chromogenic scoring when avidin–biotin detection is used (standard IHC practice).
HPA tissue IHC evidence for CDNF
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Uncertain — Low consistency between antibody staining and RNA expression data. At least one protein variant secreted, tissue location of RNA and protein might differ and correlation is complex. Pending external verification.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Fallopian tube | Glandular cells | High | Protein (IHC) | HPA → |
| Liver | Hepatocytes | High | Protein (IHC) | HPA → |
| Nasopharynx | Respiratory epithelial cells | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Oral mucosa | Squamous epithelial cells | Not detected | Protein (IHC) | HPA → |
| Parathyroid gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Soft tissue | Fibroblasts | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced CDNF IHC Tips
Troubleshoot CDNF staining in paraffin sections by checking retrieval, controls and cellular distribution before interpreting chromogenic signal.
What retrieval should I start with for CDNF in paraffin sections?
Start with citrate buffer at pH 6.0 for heat-induced retrieval at 95–98 °C for 20 min (page retrieval setting). Let sections cool in buffer, then compare staining with a matched section processed without retrieval to assess whether heating improves signal or raises background (standard IHC practice). The selected antibody has a human brain tissue-IHC image at 2.5 µg/mL, but its caption does not report retrieval conditions (A10069-1 caption). If staining remains weak, test a second retrieval condition on adjacent sections while holding antibody concentration, detection and imaging constant (standard IHC practice).
How should I troubleshoot CDNF staining after fixation?
CDNF-specific sensitivity to fixative type or fixation duration is unknown from the supplied evidence; the selected human brain IHC caption does not state its fixative (A10069-1 caption). Record fixation and processing for each specimen, and compare sections processed together before attributing a weak signal to CDNF abundance (standard IHC practice). If material permits, compare appropriately fixed specimens using the same citrate pH 6.0 retrieval at 95–98 °C for 20 min (page retrieval setting; standard IHC practice). Include a positive tissue control in each run so a failed stain can be distinguished from a specimen-specific result (standard IHC practice).
How should I assess cytoplasmic, nuclear and extracellular CDNF staining?
CDNF is annotated as secreted and has no transmembrane segment, so a sharp membrane-restricted pattern needs independent confirmation (UniProt Q49AH0). Tissue IHC reports cytoplasmic and nuclear expression in most tissues, although its staining reliability is uncertain (HPA tissue IHC). Assess cellular and extracellular signal separately, using the same exposure or microscope settings and a matched negative control to identify diffuse chromogen deposits (standard IHC practice). In brain sections, do not infer a neuronal source solely from nearby signal: a secreted protein can be detected away from its producing cell (UniProt Q49AH0 topology; HPA tissue IHC reliability description).
Can this antibody distinguish mature CDNF from its precursor or isoforms?
The record lists 2 CDNF isoforms and a signal peptide at residues 1–24, with the annotated mature chain spanning 25–187 (UniProt Q49AH0). The supplied IHC caption gives an antibody concentration of 2.5 µg/mL but no epitope map or isoform-specific validation (A10069-1 caption). Therefore, treat staining as CDNF immunoreactivity without assigning it to a particular isoform or processing state (UniProt Q49AH0; A10069-1 caption). If that distinction matters, obtain epitope information and compare orthogonal isoform evidence before interpreting compartment differences; CDNF has no annotated glycosylation sites or modified residues in this record (UniProt Q49AH0; standard IHC practice).
How can I examine CDNF by multiplex immunofluorescence?
The supplied CDNF image documents tissue IHC, while HPA lists no cell lines with ICC/IF images, so verify any IF signal independently (A10069-1 caption; HPA subcellular). Pair CDNF with a validated marker for the expected cell type and include single-label controls to check channel bleed-through (standard IF practice). Choose a fluorophore channel with low autofluorescence in the specimen, and compare unstained and secondary-only sections using identical acquisition settings (standard IF practice). For an epitope inside a cell, test mild detergent permeabilisation; for a secreted, extracellular epitope, compare a nonpermeabilised condition because CDNF is secreted and lacks a transmembrane segment (UniProt Q49AH0 topology; standard IF practice).
What should I check when CDNF chromogenic staining is diffuse or widespread?
Run a no-primary control and inspect whether deposits persist, especially around tissue edges or damaged areas (standard IHC practice). For peroxidase detection, confirm that the peroxidase block and washes were effective before adjusting primary antibody concentration or DAB development time (standard IHC practice). Widespread staining alone is insufficient evidence of specificity: HPA reports expression across most tissues but rates its tissue-IHC consistency as uncertain (HPA tissue IHC). Compare the pattern with the selected human brain image, whose antibody concentration was 2.5 µg/mL, while remembering that its caption does not specify fixation or retrieval (A10069-1 caption).
How should I quantify CDNF staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the anatomical region and cell population before scoring, then apply the same thresholds and imaging conditions to every section (standard IHC practice). For cellular staining, report the percentage of positive cells and an H-score from 0–300; for discrete positive cells, report counts per mm² (standard IHC practice). Normalise counts to the measured tissue area, and report the number of eligible cells when using percentage or H-score measures (standard IHC practice). Score cellular and extracellular staining separately because CDNF is secreted, and interpret small differences cautiously given the uncertain consistency of HPA tissue-IHC staining (UniProt Q49AH0; HPA tissue IHC).
How can I distinguish credible CDNF staining from an artefact?
A credible result should reproduce in comparable sections, agree with the positive control and disappear or substantially diminish in the no-primary control (standard IHC practice). Check cell identity: HPA reports high staining in adrenal glandular cells and low staining in cerebral cortex glial cells, but rates its overall tissue-IHC reliability as uncertain (HPA tissue IHC). Treat edge-only deposits, necrotic areas and signal persisting after omission of primary antibody as possible artefacts; review the peroxidase control if chromogen remains (standard IHC practice). Nuclear or cytoplasmic staining is reported in tissue IHC, while CDNF is annotated as secreted, so use orthogonal evidence before assigning a cellular source (HPA tissue IHC; UniProt Q49AH0).
Boster reagents
Best CDNF / Cerebral dopamine neurotrophic factor IHC Antibodies
Both anti-CDNF antibodies have human tissue IHC images; A10069-1 also has mouse brain IHC and human brain cell and mouse brain IF images (catalog image captions).
Real IHC data
Anti-CDNF Antibody
Cat # A10069-1
Real IHC data
Anti-CDNF Antibody
Cat # A10069
A10069-1 lists IHC-P and IF, with IHC images of human and mouse brain and IF images of human brain cells and mouse brain tissue (catalog applications; A10069-1 image captions). A10069 lists IHC and IF, with a paraffin-embedded human liver IHC image; no IF image is supplied (catalog applications; A10069 image captions).
Which to pick: For tissue IHC, choose A10069-1 for its human and mouse brain images and IHC-P listing; A10069’s own image supports paraffin-embedded human liver sections, but its fixative is unreported (A10069-1 applications and IHC captions; A10069 IHC caption). For IF/ICC planning, A10069-1 has IF images of human brain cells and mouse brain tissue; ICC validation is unreported (A10069-1 IF captions; catalog applications). Both list human, mouse and rat reactivity and rabbit host, but pictured IHC evidence covers human and mouse for A10069-1 and human only for A10069; clone identity is unreported (catalog reactivity and host; catalog IHC captions; catalog clone fields).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q49AH0 (CDNF_HUMAN, Cerebral dopamine neurotrophic factor).
- Human Protein Atlas. CDNF tissue IHC expression (reliability: Uncertain).
- Human Protein Atlas. CDNF subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. CDNF antibody validation summary (1 antibodies).
- Beneficial behavioral effects of chronic cerebral dopamine neurotrophic factor (CDNF) infusion in the N171-82Q transgenic model of Huntington's disease. Scientific reports 2023 — PMC9941578.
- Cerebral Dopamine Neurotrophic Factor Diffuses Around the Brainstem and Does Not Undergo Anterograde Transport After Injection to the Substantia Nigra. Frontiers in neuroscience 2019 — PMC6580362.
- Cerebral dopamine neurotrophic factor (CDNF) protects against quinolinic acid-induced toxicity in in vitro and in vivo models of Huntington's disease. Scientific reports 2020 — PMC7645584.
- Sex and age differences in mice models of effort-based decision-making and anergia in depression: the role of dopamine, and cerebral-dopamine-neurotrophic-factor. Psychopharmacology 2023 — PMC10593617.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:15489334 — UniProt-cited evidence.
- PubMed PMID:17611540 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CDNF (Cerebral dopamine neurotrophic factor). Expected localisation Cytoplasmic and nuclear tissue staining (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: A10069-1 at 2.5 μg/mL (the product's own IHC validation image is shown). Controls (HPA): positive Adrenal gland (Glandular cells); negative Adipose tissue. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet A10069-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-CDNF, 2.5 μg/mL (datasheet A10069-1); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Secreted CDNF may weaken RNA–staining agreement (HPA tissue IHC); Isoform / epitope: 2 isoforms; signal peptide 1–24 is cleaved; epitope map unknown (UniProt); Regulation: No specific expression regulator reported (UniProt). Evidence: UniProt Q49AH0, HPA tissue IHC · Uncertain, HPA ICC-IF · Secreted, Datasheet A10069-1, PMC9941578, PMC6580362. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CDNF/immunohistochemistry-ihc-guide.